Granted Patents

Innovation TCRsafe

For an accurate analysis of the T-cell receptor (TCR) repertoire, HSD’s proprietary TCRsafe-method is based on the granted patent “Methods and primer sets for high throughput PCR sequencing” (EP2746405B1). The technology featuring an intrinsic contamination protection system effectively prevents cross-sample-contaminations, which is of great advantage considering the distinct sensitivity of current next generation sequencing (NGS) technologies. Furthermore, employing a synthetic TCRbeta reference template, all primers were carefully titrated, to allow even amplification rates for all possible V/J-combinations. The method is applied to the balanced high throughput amplification and sequencing of TCR repertoires. E.g. of tumor-infiltrating lymphocytes (TIL), corresponding adjacent normal tissue and/or autologous peripheral blood cells. This technology is a prerequisite for the identification of dominant, tumor-specific T cells and their TCRs and applied to lung cancer, breast cancer, ovarian cancer, prostate cancer, melanoma specimens, etc.

 

Innovation Method for providing tumor-specific T cells

HSD’s invention “Method for providing tumor-specific T cells” (EP3180433B1) encompasses the quantitative TCRsafe high throughput TCR repertoire analysis of TIL compared to lymphocytes infiltrating adjacent corresponding normal tissue (and/ or present in peripheral blood) and the in-house TCR integrate software, which enables the identification of the tumor-specific T cell receptor (TCR) repertoire for each individual patient. Complete decoding of paired alpha and beta chains of tumor-specific TCRs facilitates synthesis and cloning of TCRs that can be applied to genetic engineering of patients’ autologous T cells. These engineered T cells are used as tumor-specific probes for the discovery of tumor antigens.  They can also be used for adoptive T cell therapy (see home page TheryCell GmbH http://www.therycell.com/en/).